-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 27, Junshi Bio announced that the anti-TIGIT monoantigen JS006 injection was approved for clinical trials of the drug.
JS006 is the company's own research and development of specific anti-TIGIT monoclonal antibody injection.
preclinical results show that JS006 can specificly block TIGIT-PVR inhibition path, stimulate the activity of lethal immune cells, and secrete tumor killer factors.
TIGIT (T cell immunoglobulin and ITIM domain, T-cell immunoglobulin and TIIM domain) is an inhibitory subject common to emerging NK cells and T-cells, which binds to highly expressed PVR subjects on tumor cells to mediate inhibitory signals of immune response, thereby directly ensuring that the contents of this bulletin are free of false records, misleading statements or material omissions, and are legally responsible for the authenticity, accuracy and completeness of their contents.
inhibits the killing of tumor cells by NK and T cells, similar to PD-1's inhibition of T cells.
preclinical trials have shown that anti-TIGIT antibodies and anti-PD-1/PD-L1 antibodies can act in synergetic anti-tumor effects.
combination of the two is a promising cancer treatment strategy that promises to increase patient response to immunotherapy and expand the range of people who may benefit.
, there are no similar target products at home and abroad have been approved for listing.
